Vanda Pharmaceuticals (VNDA) Receives Daily Media Sentiment Score of 0.11
News headlines about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.6013547184204 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Vanda Pharmaceuticals Inc. (VNDA) sticks almost -3.79% in last 5 trades – Nasdaq Fortune (press release) (nasdaqfortune.com)
- $44.00 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter (americanbankingnews.com)
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018 (finance.yahoo.com)
- Charting the Vanda Pharmaceuticals Inc. (VNDA): does technical analysis work? – Wall Street Morning (wallstreetmorning.com)
- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Sells 8568 Shares of Stock – Theafricom (theafricom.com)
Shares of Vanda Pharmaceuticals (VNDA) opened at $15.50 on Tuesday. Vanda Pharmaceuticals has a 52 week low of $11.90 and a 52 week high of $18.99. The company has a market capitalization of $696.38, a price-to-earnings ratio of -48.44 and a beta of 1.23.
In related news, CFO James Patrick Kelly sold 9,155 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the sale, the chief financial officer now owns 144,721 shares of the company’s stock, valued at $2,221,467.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Gunther Birznieks sold 8,568 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the sale, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The disclosure for this sale can be found here. Insiders sold 209,483 shares of company stock valued at $3,205,205 in the last ninety days. 7.60% of the stock is currently owned by insiders.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.